Ozempic cost per signed retainer
Ozempic (GLP-1 agonist gastroparesis) carries a cost per signed retainer of $4,200–$6,100 in Q1 2026, current as of March 31, 2026, at a 7–11% signed rate and a high qualification tier. The litigation is active. Sample size and confidence interval for this row are not available; the reason is stated on each figure below rather than omitted.
Data as of Updated Q1 2026 release
CPR range · Q1 2026
$4,200 – $6,100
Median: n/a — Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.
Signed rate
7–11%
Share of exclusive leads that become signed retainers.
Qualification tier
High
Relative difficulty of clearing this tort's qualifying criteria.
Status
Active
As published in the Q1 2026 release.
Sample size
n/a
Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.
Confidence interval
n/a
Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.
Unverified
No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price.
What third-party verification would involveOzempic CPR over time
The series for Ozempic starts at Q1 2026. Mass Tort Marketing Agency holds one published quarter of per-tort data for this tort, so there is no trend line to draw yet — the single point is shown below, and a second point will appear when the next quarter publishes.
| Quarter | CPR low | CPR high | Note |
|---|---|---|---|
| Q4 2024 | n/a | n/a | No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026. |
| Q1 2026 | $4,200 | $6,100 | Published. |
What qualifies a Ozempic claimant
Ozempic or other GLP-1 agonist use plus a documented gastroparesis diagnosis — not simple nausea or GI discomfort.
Falloff: 28%. Stated as a single current figure (28%), not a range.
Active — what that means for acquisition
Active, the newest high-volume tort in the benchmark, and criteria are still evolving. The low end of the signed-rate band reflects that many self-reporting claimants have GI symptoms that do not rise to gastroparesis on clinical evaluation. MDL leadership has telegraphed further narrowing in 2026, likely requiring gastric emptying scintigraphy documented within a defined window of GLP-1 use. Firms anticipating that narrowing pre-screen for motility testing and refuse to sign without it: signed volume drops 30-40% but falloff falls to 12-15%, improving effective CPR 18-22%.
Ozempic cost per lead
This dataset does not publish a cost-per-lead figure for Ozempic, and no CPL value is shown here rather than being derived from the CPR band. The two are related by the signed rate — CPL is approximately CPR × signed rate — but running that multiplication against a published interquartile band produces a number that looks measured and is not, so it is left out. What the benchmark does state is the signed rate: 7–11% of exclusive Ozempic leads become signed retainers that survive the 30-day falloff window. If you have your own CPL from a vendor quote, that signed rate is the multiplier that turns it into a comparable CPR.
Download this row
How to cite this page
Suggested citation:
Mass Tort Marketing Agency. "Ozempic (GLP-1 agonist gastroparesis) cost per signed retainer." Q1 2026 CPR Benchmark, published April 24, 2026. https://www.masstortmarketingagency.com/benchmarks/ozempic
- Canonical URL:
- https://www.masstortmarketingagency.com/benchmarks/ozempic
- License:
- CC BY 4.0 — reuse permitted with attribution to Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/
Citing a number that must stay stable? Point at a dated snapshot instead of the live page — snapshot files never change.